• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
13JulJuly 13, 2026

PROTAC LRRK2 Degraders Reduce Pathological Tau and Modulate Endolysosomal–Neuroinflammatory Pathways in Translational Model Systems

13JulJuly 13, 2026

AAIC 2026

03JunJune 3, 2026

ARV-393, a PROTAC BCL6 Degrader, Combined With the CD20×CD3 Bispecific Glofitamab in a Preclinical Model of HGBCL

01JunJune 1, 2026

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, as Monotherapy in Patients With Advanced NHL or Combined With Glofitamab in Patients With DLBCL

21AprApril 21, 2026

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, as Monotherapy in Patients With Advanced NHL or Combined With Glofitamab in Patients With DLBCL

21AprApril 21, 2026

Preclinical Antitumor and Immunomodulatory Activity of ARV-6723, a PROTAC HPK1 Degrader, Versus ICIs

21AprApril 21, 2026

Preclinical Efficacy of a PROTAC Pan-KRAS Degrader in a KRAS G12D Syngeneic Mouse Model and Concurrent Immune TME Changes

18MarMarch 18, 2026

AD/PD 2026

17MarMarch 17, 2026

Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants With Parkinson’s Disease

07MarMarch 7, 2026

AACR RAS 2026

12Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE